Prelude Therapeutics Incorporated
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Krishna Vaddi
- Full Time Employees
- 79
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 175 Innovation Boulevard Wilmington DE United States of America 19805
- IPO Date
- Sep 25, 2020
- CIK
- 0001678660
- Website
- preludetx.com
- Similar Companies
- Business
- Prelude Therapeutics Incorporated (Nasdaq: PRLD) is a clinical-stage precision oncology company that discovers and develops small molecule therapies targeting key driver mechanisms in genomically defined cancers with high unmet needs. The company's diversified pipeline comprises highly selective targeted protein degraders and inhibitors, including KAT6A degraders for ER-positive breast cancer and other solid tumors; mutant selective JAK2V617F JH2 inhibitors for myeloproliferative neoplasms; selective CDK9 inhibitors such as PRT2527 for solid tumors and hematological malignancies; next-generation CDK4/6 inhibitors such as PRT3645 for advanced solid tumors; and degrader antibody conjugates (DACs) incorporating novel payloads for next-generation oncology applications. Founded in 2016 and headquartered in Wilmington, Delaware, Prelude operates primarily in the United States with a focus on underserved patient populations across solid tumors and hematologic cancers. In November 2025, Prelude announced a strategic business update that included pausing development of its SMARCA2 degrader program, including PRT3789, following disappointing Phase 1 data that highlighted challenges in treating aggressive SMARCA4-deficient cancers; the company concurrently entered an exclusive option agreement with Incyte Therapeutics for its preclinical mutant selective JAK2V617F JH2 inhibitor program, receiving $35 million in upfront cash and $25 million in equity investment, with potential milestone payments up to $775 million if the option is exercised. Prelude is advancing its KAT6A degrader toward clinical trials in 2026 for ER+ breast cancer and reported third quarter 2025 financial results affirming a strengthened cash position to support prioritized programs. The company also appointed Katina Dorton, J.D., MBA, to its board of directors in October 2025, adding expertise in healthcare finance and life sciences governance.
Company News
Prelude Therapeutics to Participate in the Chardan Healthcare Conference
Down 27.4% in 4 Weeks, Here's Why Prelude Therapeutics (PRLD) Looks Ripe for a Turnaround
Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Head to Head Review: Surrozen (NASDAQ:SRZN) and Prelude Therapeutics (NASDAQ:PRLD)
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock Rated “Moderate Buy” by Sell-Side Analysts
Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader
Wall Street Analysts See a 58.42% Upside in Prelude Therapeutics (PRLD): Can the Stock Really Move This High?
ADAR1 Capital Management LLC Makes New Investment in Prelude Therapeutics Incorporated $PRLD
Prelude Therapeutics (PRLD) Upgraded to Buy: Here's Why
Prelude Therapeutics Incorporated (PRLD) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Wall Street Analysts Think Prelude Therapeutics (PRLD) Could Surge 33.59%: Read This Before Placing a Bet
Financial Analysis: Prelude Therapeutics (NASDAQ:PRLD) versus Bioasis Technologies (OTCMKTS:BIOAF)
Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering
Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026
Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer
Prelude Therapeutics (NASDAQ:PRLD) vs. Aptorum Group (NASDAQ:APM) Critical Review
Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting
Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026